Biomarkers for colorectal cancer

identification through proteomics

Lynda D. Ralton, Graeme I. Murray

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Colorectal cancer is one of the most common cancers and has one of the highest cancer mortality rates. New therapies are needed in order to specifically target individual patients to reduce toxicities and improve patient outcome in the clinic. The potential for biomarker discovery to impact current understanding and outcome of colorectal cancer has yet to be fully achieved, with many potential biomarkers identified but lack of sensitivity and/or specificity in the clinical setting render them inadequate. Biomarkers can provide prognostic or predictive information, act as screening tools or therapeutic targets and improve patient survival, yet thus far their use has been elusive in colorectal cancer. Proteomic techniques are one of the most widely used tools to enable biomarker detection due to its ability to assess protein expression, activation, post-translational modifications as well as its high-throughput potential, robustness and accuracy. This review focuses on the use of proteomic techniques for the identification of potential biomarkers and the use of biomarkers in improving patient therapies.
Original languageEnglish
Pages (from-to)212-221
Number of pages10
JournalCurrent Proteomics
Volume7
Issue number3
DOIs
Publication statusPublished - Oct 2010

Fingerprint

Biomarkers
Proteomics
Colorectal Neoplasms
Post Translational Protein Processing
Toxicity
Neoplasms
Screening
Therapeutics
Chemical activation
Throughput
Sensitivity and Specificity
Survival
Mortality
Proteins

Keywords

  • colorectal cancer
  • proteomics
  • biomarkers
  • 2D gel electrophoresis
  • mass spectrometry
  • cancer mortality
  • prognostic
  • therapeutic targets
  • post-translational modifications
  • proteomic techniques
  • its high-throughput potential
  • robustness
  • adenomatous polyps
  • obesity
  • anaemia
  • obstruction
  • mutations
  • B-catenin
  • APC/B-catenin/TCF
  • adenoma
  • carcinoma
  • K-ras gene
  • EGFR inhibitors
  • TRAIL
  • apoptosis
  • TNM (tumour)
  • metastasis
  • prognosis
  • lymph
  • nodes
  • chemotherapeutic treatment
  • metastatic disease
  • oxaliplatin
  • panitumumab
  • irinotecan
  • histopathological characteriscs
  • less toxic therapy
  • inflammatory bowel disease
  • dysplasia
  • prognostic biomarkers
  • carcinoembryonic antigen

Cite this

Biomarkers for colorectal cancer : identification through proteomics. / Ralton, Lynda D.; Murray, Graeme I.

In: Current Proteomics, Vol. 7, No. 3, 10.2010, p. 212-221.

Research output: Contribution to journalArticle

@article{3188c4a9042b43fb899fa4955a2b915b,
title = "Biomarkers for colorectal cancer: identification through proteomics",
abstract = "Colorectal cancer is one of the most common cancers and has one of the highest cancer mortality rates. New therapies are needed in order to specifically target individual patients to reduce toxicities and improve patient outcome in the clinic. The potential for biomarker discovery to impact current understanding and outcome of colorectal cancer has yet to be fully achieved, with many potential biomarkers identified but lack of sensitivity and/or specificity in the clinical setting render them inadequate. Biomarkers can provide prognostic or predictive information, act as screening tools or therapeutic targets and improve patient survival, yet thus far their use has been elusive in colorectal cancer. Proteomic techniques are one of the most widely used tools to enable biomarker detection due to its ability to assess protein expression, activation, post-translational modifications as well as its high-throughput potential, robustness and accuracy. This review focuses on the use of proteomic techniques for the identification of potential biomarkers and the use of biomarkers in improving patient therapies.",
keywords = "colorectal cancer, proteomics, biomarkers, 2D gel electrophoresis, mass spectrometry, cancer mortality, prognostic, therapeutic targets, post-translational modifications, proteomic techniques, its high-throughput potential, robustness, adenomatous polyps, obesity, anaemia, obstruction, mutations, B-catenin, APC/B-catenin/TCF, adenoma, carcinoma, K-ras gene, EGFR inhibitors, TRAIL, apoptosis, TNM (tumour), metastasis, prognosis, lymph, nodes, chemotherapeutic treatment, metastatic disease, oxaliplatin, panitumumab, irinotecan, histopathological characteriscs, less toxic therapy, inflammatory bowel disease, dysplasia, prognostic biomarkers, carcinoembryonic antigen",
author = "Ralton, {Lynda D.} and Murray, {Graeme I.}",
year = "2010",
month = "10",
doi = "10.2174/157016410792928116",
language = "English",
volume = "7",
pages = "212--221",
journal = "Current Proteomics",
issn = "1570-1646",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Biomarkers for colorectal cancer

T2 - identification through proteomics

AU - Ralton, Lynda D.

AU - Murray, Graeme I.

PY - 2010/10

Y1 - 2010/10

N2 - Colorectal cancer is one of the most common cancers and has one of the highest cancer mortality rates. New therapies are needed in order to specifically target individual patients to reduce toxicities and improve patient outcome in the clinic. The potential for biomarker discovery to impact current understanding and outcome of colorectal cancer has yet to be fully achieved, with many potential biomarkers identified but lack of sensitivity and/or specificity in the clinical setting render them inadequate. Biomarkers can provide prognostic or predictive information, act as screening tools or therapeutic targets and improve patient survival, yet thus far their use has been elusive in colorectal cancer. Proteomic techniques are one of the most widely used tools to enable biomarker detection due to its ability to assess protein expression, activation, post-translational modifications as well as its high-throughput potential, robustness and accuracy. This review focuses on the use of proteomic techniques for the identification of potential biomarkers and the use of biomarkers in improving patient therapies.

AB - Colorectal cancer is one of the most common cancers and has one of the highest cancer mortality rates. New therapies are needed in order to specifically target individual patients to reduce toxicities and improve patient outcome in the clinic. The potential for biomarker discovery to impact current understanding and outcome of colorectal cancer has yet to be fully achieved, with many potential biomarkers identified but lack of sensitivity and/or specificity in the clinical setting render them inadequate. Biomarkers can provide prognostic or predictive information, act as screening tools or therapeutic targets and improve patient survival, yet thus far their use has been elusive in colorectal cancer. Proteomic techniques are one of the most widely used tools to enable biomarker detection due to its ability to assess protein expression, activation, post-translational modifications as well as its high-throughput potential, robustness and accuracy. This review focuses on the use of proteomic techniques for the identification of potential biomarkers and the use of biomarkers in improving patient therapies.

KW - colorectal cancer

KW - proteomics

KW - biomarkers

KW - 2D gel electrophoresis

KW - mass spectrometry

KW - cancer mortality

KW - prognostic

KW - therapeutic targets

KW - post-translational modifications

KW - proteomic techniques

KW - its high-throughput potential

KW - robustness

KW - adenomatous polyps

KW - obesity

KW - anaemia

KW - obstruction

KW - mutations

KW - B-catenin

KW - APC/B-catenin/TCF

KW - adenoma

KW - carcinoma

KW - K-ras gene

KW - EGFR inhibitors

KW - TRAIL

KW - apoptosis

KW - TNM (tumour)

KW - metastasis

KW - prognosis

KW - lymph

KW - nodes

KW - chemotherapeutic treatment

KW - metastatic disease

KW - oxaliplatin

KW - panitumumab

KW - irinotecan

KW - histopathological characteriscs

KW - less toxic therapy

KW - inflammatory bowel disease

KW - dysplasia

KW - prognostic biomarkers

KW - carcinoembryonic antigen

U2 - 10.2174/157016410792928116

DO - 10.2174/157016410792928116

M3 - Article

VL - 7

SP - 212

EP - 221

JO - Current Proteomics

JF - Current Proteomics

SN - 1570-1646

IS - 3

ER -